Researchers have developed engineered lipid nanoparticles (LNPs) that use crosslinked ionizable lipids to improve mRNA vaccine performance. The modified delivery system demonstrated enhanced efficacy and reduced side effects in both human cell cultures and mouse model studies.
The engineered LNPs work by boosting dendritic cell metabolism and improving the delivery of mRNA vaccines to lymph nodes, according to the research. This enhanced targeting appears to strengthen the immune response while simultaneously reducing systemic inflammation compared to conventional LNP formulations.